The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

The European Medicines Agency's safety committee said on Friday Novo Nordisk's popular weight-loss and diabetes drugs Wegovy ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

Texas reports no new measles cases for the first time since February, maintaining 742 total cases. Meanwhile, Novo Nordisk's Ozempic is linked to rare serious eye disorders, possibly causing vision ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib and abrocitinib.

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...